The Lancet Medical Imaging and Theranostics Podcast https://lancetmedicalimaging.podbean.com Editors at The Lancet Medical Imaging and Theranostics, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.

The Lancet Medical Imaging & Theranostics is a new open access journal at The Lancet Group.  The journal will publish novel and clinically impactful research in any imaging modality (including radiology, MRI, PET, ultrasonography, nuclear medicine, theranostics, and other technologies) as well as novel applications of imaging for screening, diagnosis, prognosis, and treatment of disease across all medical specialties.

You can learn more about our mission and scope at thelancet.com/medical-imaging-theranostics.

]]> Tue, 02 Jun 2026 23:38:00 -0300 https://podbean.com/?v=5.5 en Copyright 2026 All rights reserved. Health & Fitness:Medicine 1440 episodic The Lancet Medical Imaging and Theranostics The Lancet Medical Imaging and Theranostics No false https://pbcdn1.podbean.com/imglogo/image-logo/22374923/ICW_MIT_3000X3000.png The Lancet Medical Imaging and Theranostics Podcast https://lancetmedicalimaging.podbean.com 144 144 Nathalie Albert and Matthias Preusser on the NMN-BBB score Nathalie Albert and Matthias Preusser on the NMN-BBB score https://lancetmedicalimaging.podbean.com/e/nathalie-albert-and-matthias-preusser-on-the-nmn-bbb-score/ https://lancetmedicalimaging.podbean.com/e/nathalie-albert-and-matthias-preusser-on-the-nmn-bbb-score/#comments Tue, 02 Jun 2026 23:38:00 -0300 lancetmedicalimaging.podbean.com/0f560cb7-5847-39f9-8cf4-fd04f85f2716 Professor Matthias Preusser (Medical University of Vienna, Austria) and Professor Nathalie Albert (LMU University Hospital, Munich, Germany) join Editor-in-Chief Ali Landman to discuss the Nuclear Medicine Meets Neuro-oncology (NMN) Symposium, the value of multidisciplinary discussion across nuclear medicine and oncology, their Personal View: "Imaging-based classification of blood–brain barrier disruption in glioblastoma for patient selection in clinical trials: the NMN-BBB score" which emerged from the NMN Symposium in 2023, and how this new score, which semi-quantitatively measures the extent of blood-brain barrier opening within gliomas can be used to select patients for the right clinical trials and treatments.

For more on the NMN Symposium see: https://www.nmn-society.org/

Click here to read the full article: https://www.thelancet.com/journals/lanmit/article/PIIS3117-4523(26)00002-X/fulltext

]]> Professor Matthias Preusser (Medical University of Vienna, Austria) and Professor Nathalie Albert (LMU University Hospital, Munich, Germany) join Editor-in-Chief Ali Landman to discuss the Nuclear Medicine Meets Neuro-oncology (NMN) Symposium, the value of multidisciplinary discussion across nuclear medicine and oncology, their Personal View: "Imaging-based classification of blood–brain barrier disruption in glioblastoma for patient selection in clinical trials: the NMN-BBB score" which emerged from the NMN Symposium in 2023, and how this new score, which semi-quantitatively measures the extent of blood-brain barrier opening within gliomas can be used to select patients for the right clinical trials and treatments.

For more on the NMN Symposium see: https://www.nmn-society.org/

Click here to read the full article: https://www.thelancet.com/journals/lanmit/article/PIIS3117-4523(26)00002-X/fulltext

]]> The Lancet Medical Imaging and Theranostics false No 1335 1 full